ArticleBMC cancer2025
The impact of zinc and testosterone co-treatment on tumourigenesis in prostate cancer: a novel model.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundPre-clinical models play a key role in prostate cancer research, helping to understand the mechanism of the disease. The unavailability of suitable animal models in under-resourced areas, such as in sub-Saharan African (SSA) countries, presents a major barrier for them to contribute meaningfully to developing effective treatments and preventive strategies in this global effort against prostate cancer. This study investigated the use of a combination of high-dose zinc and testosterone to induce carcinogenesis in Wistar rats.
methodsThe histopathological assessment of the model prostate was carried out. In addition, the relative gene expression of common genes that are deregulated in prostate cancer such as Tmprss2, Akt1, Pdgfrβ and Tp53 were validated in the model.
resultsWe could show that, intramuscular administration of testosterone alone causes epithelial hyperplasia but did not result in abnormal glandular patterns or patterns associated with prostate carcinoma. However, administration of high dose zinc alone (10-100 mg/kg) resulted in epithelial dysplasia in all prostate lobes and was associated with papillary and tufting patterns of glandular architecture indicative of HGPIN. Moreover, administration of testosterone together with 100 mg/kg zinc resulted in tumour formation, characterized by glands with central necrosis, loss of glandular architecture and occasional presence of luminal cells in stroma. The induction significantly increased Tmprss2 expression by 789.8-fold and Akt1 expression by 2.93-fold compared to the naïve control. Combination treatment also led to a 15.89-fold rise in Pdgfrβ expression. Additionally, Tp53 expression increased 2.23-fold in the group treated with the combination.
conclusionIn summary, the zinc-testosterone model induced lesions characteristic of HGPIN with the possibility of early microinvasive adenocarcinoma, most importantly in the dorsolateral lobes, mimicking human disease characteristics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.